Results 171 to 180 of about 24,853 (244)

Successful use of ruxolitinib in steroid-refractory chronic GvHD affecting central nervous system: a case report. [PDF]

Ann Hematol
Karakulska-Prystupiuk E, Zakrzewska-Pniewska B, Tomaszewska A, Hałaburda-Rola M, Jędrzejczak WW, Basak GW.   +5 more
europepmc   +1 more source

Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study. [PDF]

Blood Adv
Ali H, Mohan S, Kishtagari A, Prchal JT, Maher K, Chai Y, Gudi G, Taverna P, Mark T, Tantravahi SK.   +9 more
europepmc   +1 more source

High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort. [PDF]

Ann Hematol
Mendicino F, Caridà G, Bruzzese A, Martino EA, Caserta S, Amodio N, Lucia E, Olivito V, Labanca C, Alvaro ME, Luciani F, Morabito F, Vigna E, Gentile M.   +13 more
europepmc   +1 more source

Severe Immune Neutropenia Responsive to Ruxolitinib. [PDF]

EJHaem
Schwarzkopf R, Chen AAY, Elsharawi I, O'Reilly T, Chen LYC.   +4 more
europepmc   +1 more source

Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool. [PDF]

Curr Oncol
Breakell T, Neri P, Staats LAN, Kramer R, Berking C, Erdmann M, Hartmann A.   +6 more
europepmc   +1 more source

BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms. [PDF]

Front Immunol
Wu C, Wang Y, Zhang Q, Li C, Chen Y, Wu Y.   +5 more
europepmc   +1 more source

Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. [PDF]

Blood
Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea D, Harris DL, Bozym DJ, Puliafito BR, Newcomb R, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R, Barselau AL, Li A, Emmanuel-Alejandro E, Cook D, Lindell K, Luk SO, Chaffee R, Yee AJ, Branagan A, Raje N, Graham CE, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani AR, Gallagher KME, Maus MV, Frigault MJ, Leick MB.   +40 more
europepmc   +1 more source

Graft-Versus-Host Disease After Liver Transplantation: Diagnostic and Therapeutic Challenges. [PDF]

Cureus
Qi J, Latif K, Sakai L, Kejriwal N, Schill A.   +4 more
europepmc   +1 more source

Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in <i>BRAF</i> V600E-mutated lung adenocarcinoma: a case report. [PDF]

Front Oncol
Chandra S, Hansraj S, Adhikari A, Ponvilawan B, Tolentino A, Bansal D.   +5 more
europepmc   +1 more source

Current status, development and challenges in the treatment of chronic graft-versus-host disease. [PDF]

Med Rev (2021)
Chen H, Mo X.
europepmc   +1 more source